Q3 Earnings Forecast for OPKO Health Issued By HC Wainwright

OPKO Health, Inc. (NASDAQ:OPK - Free Report) - HC Wainwright raised their Q3 2025 EPS estimates for shares of OPKO Health in a note issued to investors on Monday, April 7th. HC Wainwright analyst Y. Chen now forecasts that the biotechnology company will post earnings per share of ($0.07) for the quarter, up from their previous forecast of ($0.08). HC Wainwright has a "Buy" rating and a $3.00 price target on the stock. The consensus estimate for OPKO Health's current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for OPKO Health's FY2025 earnings at ($0.29) EPS.

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.09. The company had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%.

Other equities analysts have also issued research reports about the stock. StockNews.com raised shares of OPKO Health from a "sell" rating to a "hold" rating in a report on Monday, March 3rd. Barrington Research restated an "outperform" rating and issued a $2.25 price objective on shares of OPKO Health in a report on Wednesday, March 12th.

OPKO Health Stock Performance

NASDAQ:OPK traded up $0.02 during trading hours on Thursday, reaching $1.44. The stock had a trading volume of 901,810 shares, compared to its average volume of 3,932,439. The stock has a market cap of $967.03 million, a P/E ratio of -7.58 and a beta of 1.78. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The stock has a 50 day simple moving average of $1.68 and a 200 day simple moving average of $1.58. OPKO Health has a 12-month low of $1.15 and a 12-month high of $2.04.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in OPK. FMR LLC raised its stake in OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 11,089 shares during the period. Pallas Capital Advisors LLC purchased a new stake in shares of OPKO Health during the 1st quarter valued at about $43,000. Wealth Enhancement Advisory Services LLC increased its stake in OPKO Health by 75.3% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock worth $42,000 after acquiring an additional 12,417 shares during the last quarter. Orion Portfolio Solutions LLC purchased a new stake in OPKO Health during the 3rd quarter valued at $45,000. Finally, Cibc World Markets Corp purchased a new stake in shares of OPKO Health in the fourth quarter valued at $45,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Phillip Md Et Al Frost acquired 125,000 shares of OPKO Health stock in a transaction dated Thursday, April 10th. The stock was purchased at an average cost of $1.36 per share, for a total transaction of $170,000.00. Following the purchase, the chief executive officer now directly owns 214,001,448 shares of the company's stock, valued at approximately $291,041,969.28. This trade represents a 0.06 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders have bought 1,464,971 shares of company stock valued at $2,268,692 in the last ninety days. 49.69% of the stock is currently owned by company insiders.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.